Safety and Feasibility of ActivSightTM in Human
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04633512|
Recruitment Status : Enrolling by invitation
First Posted : November 18, 2020
Last Update Posted : May 4, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
ActivSightTM combines an innovative form factor and proprietary software to deliver precise, objective, real-time visualization of blood flow and tissue perfusion intraoperatively for laparoscope-based surgery. A small adaptor that fits between any existing laparoscope and camera systems and a separate light source placed along any current commercial system will deliver objective real-time tissue perfusion and blood flow information intraoperatively.
Primary Objective: To determine safety and feasibility of ActivSightTM in displaying tissue perfusion in intestinal anastomoses including colorectal and bariatric surgery.
Secondary Objective: To determine the efficacy of ActivSightTM in; (1) displaying tissue vascularity and perfusion in comparison to indocyanine green (ICG) during gastrointestinal anastomoses; and (2) displaying biliary tree during laparoscopic cholecystectomy using ICG-based intraoperative cholangiography (IOC).
|Condition or disease||Intervention/treatment||Phase|
|Acute Cholecystitis Colorectal Cancer Diverticulitis, Colonic Obesity, Morbid Inflammatory Bowel Diseases||Device: ActivSight||Not Applicable|
- This is a feasibility study designed to evaluate safety and feasibility of ActivSightTM in gastrointestinal anastomoses and cholecystectomy.
- Safety will be determined through clinical assessments and evaluation of any adverse event.
- Feasibility will be determined through technically successful completion of intended visualization.
- Assessment of preliminary efficacy will be performed through analysis of any intraoperative decisions made based on visual display as compared to standard endoscopic approach, or non-inferiority to ICG-based visualization and usability.
- Patients outcome and follow up to Postoperative day 28 will be monitored for clinical outcome.
- Target enrollment for the assessment of 40 patients; 26 evaluating intestinal anastomoses cases (including bariatric and colorectal cases); and 14 evaluating laparoscopic cholecystectomy. Stopping rules are triggered following the first 6 patients and a comparison group 6 patients in ICG-based treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Target enrollment is 40 patients. Feasibility will be studied under two categories of operations: feasibility in patients undergoing intestinal anastomoses for bariatric or colorectal surgery (n=26); and feasibility in patients undergoing cholecystectomy (n=14).|
|Masking:||None (Open Label)|
|Primary Purpose:||Device Feasibility|
|Official Title:||Safety and Feasibility of ActivSightTM Laser Speckle Imaging in Visualization of Tissue Perfusion and Vasculature in Human|
|Actual Study Start Date :||November 17, 2020|
|Estimated Primary Completion Date :||January 2024|
|Estimated Study Completion Date :||January 2024|
Experimental: ActivSight Group
Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=26) Patients undergoing cholecystectomy with ActivSight (n=14)
Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
- Incidence of Adverse Events in 28 days following use of ActivSightTM [ Time Frame: 28 days ]
To determine safety of ActivSightTM in patients undergoing intestinal anastomoses, as defined through clinical assessments and evaluation of use related adverse events intraoperatively and a routine follow up at 28 days following surgery. ActivSightTM will be deemed safe if hardware (adaptor or light source)-related major (serious) adverse event is encountered in the treated patients and if less than 2 hardware-related minor adverse events are encountered.
Adverse events will be summarized descriptively and tabulations on the type, severity, and relationship to application will be performed and any changes of outcomes from baseline on follow up will be examined using the nonparametric Wilcoxon rank test.
- Preparation time of ActivSightTM. [ Time Frame: 1 day ]Rate on a scale of 1-5 (1 = Difficult to use or Unsatisfied - 5 = no training required or very satisfied): How easy was ActivSight to set up?
- Latency of display of ActivSightTM. [ Time Frame: 1 day ]Rate on a scale of 1-5 (1 = Difficult to use or Unsatisfied - 5 = no training required or very satisfied): How specifically did ActivSight display the intended field and the target tissue of interest?
- Resolution of display of ActivSightTM. [ Time Frame: 1 day ]Rate on a scale of 1-5 (1 = Difficult to use or Unsatisfied - 5 = no training required or very satisfied): How was the display quality of ActivSight on the intended field and target tissue of interest?
- Specificity of display of ActivSightTM. [ Time Frame: 1 day ]Specificity of display will serve as an outcome for feasibility. Yes/No question for surgeon: "Does the perfusion information displayed by ActivSightTM reflect the expected pattern of blood flow interruption?"
- Usability of ActivSightTM by surgeon, as quantified by Likert scale. [ Time Frame: 1 day ]Likert scale ratings will serve as an outcome for feasibility. Scale 1-5 question (1=strongly disagree, 2=slightly disagree, 3=neutral, 4=slightly agree, 5=strongly agree): "ActivSightTM was easy to use while operating."
- Support personnel satisfaction with ActivSightTM, as quantified by Likert scale. [ Time Frame: 1 day ]Likert scale ratings will serve as an outcome for feasibility. Scale 1-5 question (1=strongly disagree, 2=slightly disagree, 3=neutral, 4=slightly agree, 5=strongly agree): "ActivSightTM was easy to set up for the procedure."
- Ability of ActivSightTM to display perfusion. [ Time Frame: 1 day ]ActivSightTM ability to display perfusion at a tissue level during gastrointestinal anastomoses is measured by the following Yes/No question for the surgeon: "Does ActivSightTM display tissue perfusion of the anatomy during anastomoses in comparison to ICG?"
- Ability of ActivSightTM to display blood vessels. [ Time Frame: 1 day ]ActivSightTM ability to display blood vessels during gastrointestinal anastomoses is measured by the following Yes/No question for the surgeon: "Does ActivSightTM display vascularity of the anatomy during anastomoses in comparison to ICG?"
- Ability of ActivSightTM to display biliary tree. [ Time Frame: 1 day ]The clinical metrics for displaying biliary tree will be evaluated using the following question: "Which of the following biliary structures are you able to identify using ActivSightTM with ICG? (Select all that apply): common bile duct (CD), right hepatic duct (RHD), common hepatic duct (CHD), common bile duct (CBD), cystic common bile duct junction (CCBDJ), cystic gallbladder junction (CGJ), accessory ducts (AD)."
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- All patients age >= 18 years old undergoing laparoscopic or robot assisted intestinal anastomoses, or all patients age >= 18 years old who are planned for laparoscopic cholecystectomy; spoken command and literacy in the native language spoken at each participating center; ability to understand and follow study procedures; and having provided signed consent.
- All patients with a clinical suspicion and diagnosis of benign or malignant, small or large bowel lesions requiring surgical resection.
- All patients with clinical suspicion and diagnosis of symptomatic cholelithiasis or cholecystitis planned for cholecystectomy.
- Typical imaging as per standard workup findings including US, CT and/or MRI. Plain radiographs and contrast imaging may be obtained by referring physicians and are helpful for confirming the clinical diagnosis.
- Any bariatric patients undergoing gastric sleeve or bypass.
- Any pediatric patient undergoing laparotomy for necrotizing enterocolitis
- Location of pathology or resected segment:
- Target lesions can be located in any fore-, mid- or hindgut segments requiring reconstruction and anastomoses.
- Prior therapy:
- Patients with prior surgery are eligible for enrollment.
- Hemoglobin > 9 g/dL
- Platelet count ≥75,000/μL (may receive transfusions)
- Normal prothrombin time, tested prothrombin, and international normalized ratio < 1.5 x upper limit of normal (ULN) (including patients on prophylactic anticoagulation)
- Renal function: Age-adjusted normal serum creatinine derived from Schwartz formula for estimating glomerular filtration rate by the Centers for Disease Control (CDC) or a creatinine clearance ≥60 mL/min/1.73 m2 for safe
- Adequate pulmonary function: Defined as no dyspnea at rest, and a pulse oximetry >94% on room air if there is clinical indication for determination.
- There is no exclusion criteria for ActivSightTM for gastrointestinal resection.
- Patients assigned to FDA cleared ICG-based visualization are contraindicated for any chronic renal dysfunction, potential drug interaction, history of allergy to ICG or anaphylaxis, and pregnancy.
- Patients eligible for cholecystectomy, exclusion criteria include known allergy to iodides; known history of cholangitis, pancreatitis, prior common bile duct injury, coagulopathy or known, preexisting liver disease; pregnancy or breast-feeding; or being of reproductive age with pregnancy possible and not ruled out.
- Patients currently in any investigational agents.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04633512
|United States, New York|
|Kaleida Health, University of Buffalo|
|Buffalo, New York, United States, 14203|
|United States, Texas|
|Memorial Hermann Texas Medical Center|
|Houston, Texas, United States, 77030|
|Memorial Hermann Sugar Land Hospital|
|Sugar Land, Texas, United States, 77479|
Documents provided by Activ Surgical:
|Responsible Party:||Activ Surgical|
|Other Study ID Numbers:||
|First Posted:||November 18, 2020 Key Record Dates|
|Last Update Posted:||May 4, 2021|
|Last Verified:||April 2021|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Product Manufactured in and Exported from the U.S.:||No|
robot assisted surgery
laser speckle contrast imaging
Inflammatory Bowel Diseases
Digestive System Diseases
Biliary Tract Diseases